Letermovir prophylaxis reduces the risk for CMV reactivation after allogeneic stem cell transplantation

被引：0
|
作者：
Koch, K. [1 ]
Herhaus, P. [1 ]
Osswald, L. [1 ]
Braitsch, K. [1 ]
Bassermann, F. [1 ]
Verbeek, M. [1 ]
机构：
[1] Tech Univ Munich, Munich, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V639
引用
下载
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [1] Letermovir Prophylaxis Reduces The Risk for Cmv Infection After Stem Cell Transplantation
    Koch, Katrin
    Osswald, Lena
    Miller, Isabella
    Braitsch, Krischan
    Herhaus, Peter
    Bassermann, Florian
    Verbeek, Mareike
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 232 - 233
  • [2] RISK FACTORS FOR CMV REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION AND INITIAL EXPERIENCE WITH LETERMOVIR PROPHYLAXSIS
    Sperotto, A.
    Candoni, A.
    Cerno, M.
    De Marchi, R.
    Cigana, C.
    Radici, V.
    Battista, M. L.
    Colasante, F.
    Rosignoli, C.
    Dubbini, V.
    Stella, R.
    Geromin, A.
    Patriarca, F.
    Fanin, R.
    HAEMATOLOGICA, 2019, 104 : 131 - 131
  • [3] Prolonged use of letermovir as CMV reactivation prophylaxis significantly reduces the risk of CMV reactivation in persistently immunocompromised stem cell transplant patients
    Koch, K.
    Osswald, L.
    Miller, I.
    Braitsch, K.
    Goetze, K.
    Bassermann, F.
    Herhaus, P.
    Verbeek, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 242 - 242
  • [4] Risk factor analysis for cytomegalovirus reactivation under prophylaxis with letermovir after allogeneic hematopoietic stem cell transplantation
    Mizuno, Kota
    Sakurai, Masatoshi
    Kato, Jun
    Yamaguchi, Kentaro
    Abe, Ryohei
    Koda, Yuya
    Kataoka, Keisuke
    Mori, Takehiko
    TRANSPLANT INFECTIOUS DISEASE, 2022, 24 (06)
  • [5] Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: Α Retrospective Single Center Analysis
    Koch, Katrin
    Osswald, Lena
    Miller, Isabella
    Braitsch, Krischan
    Goetze, Katharina
    Bassermann, Florian
    Herhaus, Peter
    Verbeek, Mareike
    ANTICANCER RESEARCH, 2022, 42 (11) : 5431 - 5441
  • [6] CMV REACTIVATION AFTER STOPPING LETERMOVIR PRIMARY PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS
    Chavaz, Lara
    Royston, Lena
    Masouridi-Levrat, Stavroula
    Mamez, Anne-Claire
    Giannotti, Federica
    Morin, Sarah
    Van Delden, Christian
    Chalandon, Yves
    Neofytos, Dionysios
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 93 - 93
  • [7] Letermovir prophylaxis reduces peak cmv titres and need for additional antiviral treatment in allogeneic haematopoietic stem cell transplantation
    Buckton, M.
    Firbank, S.
    Bigley, V.
    Collin, M.
    Hurst, E.
    Publicover, A.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 275 - 275
  • [8] Clinical Efficacy of Letermovir Prophylaxis for CMV Infection after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Experience
    Satake, Atsushi
    Ichikawa, Jun
    Saito, Ryo
    Konishi, Akiko
    Hotta, Masaaki
    Nakanishi, Takahisa
    Nakaya, Aya
    Fujita, Shinya
    Ito, Tomoki
    Ishii, Kazuyoshi
    Nomura, Shosaku
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 479 - 480
  • [9] Efficacy of Letermovir for Prophylaxis of CMV Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Multi Center Retrospective Analysis among Japanese Patients
    Mori, Yasuo
    Yoshimoto, Goichi
    Eto, Tetsuya
    Nagafuji, Koji
    Iwasaki, Hiromi
    Ito, Yoshikiyo
    Ohno, Yuju
    Kamimura, Tomohiko
    Ogawa, Ryosuke
    Numata, Akihiko
    Kato, Koji
    Takenaka, Katsuto
    Miyamoto, Toshihiro
    Akashi, Koichi
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 469 - 470
  • [10] Letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplantation
    Azharuddin, Md
    Sharma, Manju
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 149 - 149
12345